Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12219020 | 0.81 | PPM1B (0.42) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| SCHEMBL12194210 | 0.80 | PPM1B (0.39) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| SCHEMBL422879 | 0.80 | MAPT (0.46) | MAPTCYP2C19CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8647198 | 0.80 | MAPT (0.39) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| SCHEMBL19318890 | 0.80 | MAPT (0.39) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| SCHEMBL12218998 | 0.78 | PPM1B (0.37) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| SCHEMBL15712143 | 0.77 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTLMNA | |
| SCHEMBL16821402 | 0.77 | PPM1B (0.42) | PPM1BPTPN1PPP1CCMAPTCYP2C19 | |
| Formic Acid SCHEMBL28812219 | 0.74 | MAPT (0.41) | MAPTCYP2C19CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25467328 | 0.74 | PPM1B (0.50) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613408-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-110914271-B | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2802326-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-1052246-B1 | FLUORINE-CONTAINING AMINO ACID DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6316498-B1 | FOR THERAPY AND PROPHYLAXIS OF PSYCHIATRIC DISORDERS SUCH AS SCHIZOPHRENIA, ANXIETY, ASSOCIATED DISEASES, DEPRESSION, BIPOLAR DISTURBANCE AND EPILEPSY, NEUROLOGICAL DISEASES SUCH AS DRUG ADDICTION, COGNITION DISORDER, ALZHEIMER'S DISEASE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| EP-1052246-A1 | FLUORINE-CONTAINING AMINO ACID DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PPM1B 145/4885PTPN1 344/4885PPP1CC 290/4885 |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | PPM1B 4474/4885PTPN1 4701/4885PPP1CC 4138/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PPM1B 145/4885PTPN1 344/4885PPP1CC 290/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | PPM1B 4474/4885PTPN1 4701/4885PPP1CC 4138/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PPM1B 145/4885PTPN1 344/4885PPP1CC 290/4885 |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | PPM1B 4474/4885PTPN1 4701/4885PPP1CC 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.